



The Annenberg Academy for Team-Based Care

Interprofessional Care of Patients with Hemophilia

REFERENCES

1. Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. *Haemophilia*. 2020;26(Suppl 6):1–158. doi:10.1111/hae.14046
2. National Bleeding Disorders Foundation. MASAC Document 267 - MASAC Recommendation Concerning Prophylaxis for Hemophilia A and B with and without inhibitors. Published April 27, 2022. Accessed October 22, 2024. <https://www.bleeding.org/healthcare-professionals/guidelines-on-care/masac-documents/masac-document-267-masac-recommendation-concerning-prophylaxis-for-hemophilia-a-and-b-with-and-without-inhibitors>
3. Callaghan MU, Negrier C, Paz-Priel I, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. *Blood*. 2021;137(16):2231–2242. doi:10.1182/blood.2020009217
4. Hermans C, Skinner MW, Gentile B, et al. Pain-related quality of life outcomes in people with haemophilia A receiving emicizumab: A post hoc analysis of the HAVEN 1, 3 and 4 and STASEY studies. *Haemophilia*. 2025;31(1):87–98. doi:10.1111/hae.15134
5. Shima M, Suzuki N, Nishikii H, et al. Final analysis results from the AGEHA study: Emicizumab prophylaxis for acquired hemophilia A with or without immunosuppressive therapy. *Thromb Haemost*. 2025;125(5):449–459. doi:10.1055/a-2384-3585
6. Lentz SR, Chowdary P, Gil L, et al. FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic. *J Thromb Haemost*. 2024;22(4):990–1000. doi:10.1016/j.jtha.2023.12.016
7. Persson P, Amstrup AB, Coester HV, Matysina I, Bas S. Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adults. *Res Pract Thromb Haemost*. 2023;7(6):102181. doi:10.1016/j.rpth.2023.102181
8. Chowdary P, Fischer K, Collins PW, et al. Modeling to predict Factor VIII levels associated with zero bleeds in patients with severe hemophilia A initiated on tertiary prophylaxis. *Thromb Haemost*. 2020;120(5):728–736. doi:10.1055/s-0040-1709519
9. Matsushita T, Shapiro A, Abraham A, et al. Phase 3 trial of concizumab in hemophilia with inhibitors. *N Engl J Med*. 2023;389(9):783–794. doi:10.1056/NEJMoa2216455
10. Chowdary P, Angchaisuksiri P, Apte S, et al. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial. *Lancet Haematol*. 2024;11(12):e891–e904. doi:10.1016/s2352-3026(24)00307-7
11. Young G, Srivastava A, Kavakli K, et al. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. *Lancet*. 2023;401(10386):1427–1437. doi:10.1016/s0140-6736(23)00284-2
12. Srivastava A, Rangarajan S, Kavakli K, et al. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial. *Lancet Haematol*. 2023;10(5):e322–e332. doi:10.1016/s2352-3026(23)00037-6
13. Young G, Kavakli K, Klamroth R, et al. Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study. *Blood*. 2025;145(25):2966–2977. doi:10.1182/blood.2024027008
14. Matino D, Palladino A, Taylor CT, et al. Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial. *Blood*. 2025;146(14):1654–1663. doi:10.1182/blood.2024027468
15. Mahlangu J, Luis Lamas J, Cristobal Morales J, et al. Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results. *Br J Haematol*. 2023;200(2):240–248. doi:10.1111/bjh.18495
16. Pipe SW, Leebeek FWG, Recht M, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. *N Engl J Med*. 2023;388(8):706–718. doi:10.1056/NEJMoa2211644



The Annenberg Academy for Team-Based Care

Interprofessional Care of Patients with Hemophilia

17. von Drygalski A, Gomez E, Giermasz A, et al. Completion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years. *Blood Adv.* 2025;9(14):3543–3552. doi:10.1182/bloodadvances.2024015291
18. Cuker A, Kavakli K, Frenzel L, et al. Gene therapy with fidanacogene elaparvovec in adults with hemophilia B. *N Engl J Med.* 2024;391(12):1108–1118. doi:10.1056/NEJMoa2302982
19. Rasko JEJ, Samelson-Jones BJ, George LA, et al. Fidanacogene elaparvovec for hemophilia B - A multiyear follow-up study. *N Engl J Med.* 2025;392(15):1508–1517. doi:10.1056/NEJMoa2307159
20. Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. *N Engl J Med.* 2022;386(11):1013–1025. doi:10.1056/NEJMoa2113708
21. Symington E, Rangarajan S, Lester W, et al. Valoctocogene roxaparvovec gene therapy provides durable haemostatic control for up to 7 years for haemophilia A. *Haemophilia.* 2024;30(5):1138–1147. doi:10.1111/hae.15071
22. World Health Organization. Framework for Action on Interprofessional Education & Collaborative Practice. Published 2010. Accessed March 6, 2024. https://iris.who.int/bitstream/handle/10665/70185/WHO_HRH_HPN_10.3_eng.pdf?sequence=1
23. Prado P, Norman RS, Vasquez L, et al. An interprofessional skills workshop to teach family caregivers of people living with dementia to provide complex care. *J Interprof Educ Pract.* 2022;26:100481. doi:10.1016/j.xjep.2021.100481
24. Schoeffler A, Bashian EJ, Callender N, et al. Implementation of a COVID-19 vaccine emergency department education program for underserved communities. *Cureus.* 2022;14(11):e30972. doi:10.7759/cureus.30972
25. Stewart-Lynch A, Lombardo S, Ceriani D, Mastrangelo S. Well Child Wednesdays: An interprofessional pilot-program to increase pediatric immunizations Post-COVID. *J Interprof Educ Pract.* 2023;31:100606. doi:10.1016/j.xjep.2023.100606
26. Pariser P, Pham TT, Brown JB, Stewart M, Charles J. Connecting people with multimorbidity to interprofessional teams using telemedicine. *Ann Fam Med.* 2019;17(Suppl 1):S57–S62. doi:10.1370/afm.2379
27. Hammick M, Freeth D, Koppel I, Reeves S, Barr H. A best evidence systematic review of interprofessional education: BEME Guide no. 9. *Med Teach.* 2007;29(8):735–751. doi:10.1080/01421590701682576
28. Reeves S, Fletcher S, Barr H, et al. A BEME systematic review of the effects of interprofessional education: BEME Guide No. 39. *Med Teach.* 2016;38(7):656–668. doi:10.3109/0142159x.2016.1173663
29. White DB, Angus DC, Shields AM, et al. A randomized trial of a family-support intervention in intensive care units. *N Engl J Med.* 2018;378(25):2365–2375. doi:10.1056/NEJMoa1802637
30. Guck TP, Potthoff MR, Walters RW, Doll J, Greene MA, DeFreece T. Improved outcomes associated with interprofessional collaborative practice. *Ann Fam Med.* 2019;17(Suppl 1):S82. doi:10.1370/afm.2428
31. Cahn PS. How interprofessional collaborative practice can help dismantle systemic racism. *J Interprof Care.* 2020;34(4):431–434. doi:10.1080/13561820.2020.1790224
32. White-Williams C, Shirey M, Eagleson R, Clarkson S, Bittner V. An interprofessional collaborative practice can reduce heart failure hospital readmissions and costs in an underserved population. *J Card Fail.* 2021;27(11):1185–1194. doi:10.1016/j.cardfail.2021.04.011
33. Kaiser L, Conrad S, Neugebauer EAM, Pietsch B, Pieper D. Interprofessional collaboration and patient-reported outcomes in inpatient care: a systematic review. *Syst Rev.* 2022;11(1):169. doi:10.1186/s13643-022-02027-x
34. Mäki-Asiala M, Axelin A, Pölkki T. Parents' experiences with interprofessional collaboration in neonatal pain management: A descriptive qualitative study. *J Clin Nurs.* 2023;32(21-22):7860–7872. doi:10.1111/jocn.16857
35. Interprofessional Education Collaborative. IPEC Core Competencies for Interprofessional Collaborative Practice: Version 3. Published November 20, 2023. Accessed September 15, 2025. https://www.ipeccollaborative.org/assets/core-competencies/IPEC_Core_Competencies_Version_3_2023.pdf



The Annenberg Academy for Team-Based Care

Interprofessional Care of Patients with Hemophilia

36. Millstein LS, Allen J, Bellin MH, et al. An interprofessional training to improve advance care planning skills among medicine, nursing, and social work students. *J Interprof Educ Pract.* 2020;21:100382. doi:10.1016/j.xjep.2020.100382
37. Nicholson L, Ortiz MV, Wang Y, Walsh H, Ottolini MC, Agrawal D. Successful implementation of a novel collaborative interprofessional educational curriculum for nurses and residents in a pediatric acute care setting. *J Interprof Educ Pract.* 2019;17:100284. doi:10.1016/j.xjep.2019.100284
38. Rider EA, Chou C, Abraham C, et al. Longitudinal faculty development to improve interprofessional collaboration and practice: a multisite qualitative study at five US academic health centres. *BMJ Open.* 2023;13(4):e069466. doi:10.1136/bmjopen-2022-069466
39. National Bleeding Disorders Foundation. History from 2 AD to the present. Published 2025. Accessed October 17, 2025. <https://www.bleeding.org/bleeding-disorders-a-z/overview/history>
40. Valentino LA, Baker JR, Butler R, et al. Integrated hemophilia patient care via a national network of care centers in the United States: A model for rare coagulation disorders. *J Blood Med.* 2021;12:897–911. doi:10.2147/jbm.S325031
41. Pai M, Key NS, Skinner M, et al. NHF-McMaster Guideline on Care Models for Haemophilia Management. *Haemophilia.* 2016;22(Suppl 3):6–16. doi:10.1111/hae.13008
42. Skinner MW, Soucie JM, McLaughlin K. The national haemophilia program standards, evaluation and oversight systems in the United States of America. *Blood Transfus.* 2014;12(Suppl 3):e542–e548. doi:10.2450/2014.0019-14s
43. Riske B, Shearer R, Baker JR. Patient satisfaction with US Hemophilia Treatment Center care, teams and services: The first national survey. *Haemophilia.* 2020;26(6):991–998. doi:10.1111/hae.14176
44. St-Louis J, Chowdary P, Dolan G, et al. Multidisciplinary team care of patients with hemophilic arthropathy: A qualitative assessment of contemporary practice in the UK and Canada: Canada/UK: MDT practices for hemophilia. *Clin Appl Thromb Hemost.* 2022;28:10760296211070002. doi:10.1177/10760296211070002
45. Yeung CH, Santesso N, Pai M, et al. Care models in the management of haemophilia: a systematic review. *Haemophilia.* 2016;22(Suppl 3):31–40. doi:10.1111/hae.13000
46. Bartlett DL, Schnur KM, Wilson AK, Moorman SS. Defining the micro and macro roles of a hemophilia treatment center social worker in the United States from an interdisciplinary team perspective. *Haemophilia.* 2022;28(6):e164–e171. doi:10.1111/hae.14612
47. Geary MK, Kachalsky E, Parnes A. The actual and ideal roles of haemophilia treatment centre social workers in the United States and the barriers to ideal roles. *Haemophilia.* 2021;27(6):e683–e689. doi:10.1111/hae.14414
48. Königs C, Motwani J, Jiménez-Yuste V, Blatný J. Teenagers and adolescents with hemophilia-Need for a specific approach. *J Clin Med.* 2024;13(17):5121. doi:10.3390/jcm13175121